{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:44:22Z","timestamp":1790732662046,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jchromb.2024.124217","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T07:06:13Z","timestamp":1719212773000},"page":"124217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Quantification and analyses of seven tyrosine kinase inhibitors targeting hepatocellular carcinoma in human plasma by QuEChERS and UPLC-MS\/MS"],"prefix":"10.1016","volume":"1242","author":[{"given":"Yan","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangning","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2024.124217_b0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/2213988501812010009","article-title":"Hepatocellular carcinoma: causes, mechanism of progression and biomarkers","volume":"12","author":"Singh","year":"2018","journal-title":"Curr. Chem. Genom. Transl. Med."},{"key":"10.1016\/j.jchromb.2024.124217_b0010","first-page":"764","article-title":"Andrographolide, a novel bioactive phytoconstituent encapsulated in sustained release biodegradable nanoparticles","volume":"9","author":"Bothiraja","year":"2011","journal-title":"Int. J. Nanotech."},{"key":"10.1016\/j.jchromb.2024.124217_b0015","first-page":"1031","article-title":"Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study, Japan","volume":"11","author":"Yoshihiko","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jchromb.2024.124217_b0020","first-page":"1303","article-title":"Detection of early tumor response to axitinib in advanced hepatocellular carcinoma by dynamic contrast enhanced ultrasound","volume":"6","author":"Glen","year":"2016","journal-title":"Ultrasound Med. Biol."},{"key":"10.1016\/j.jchromb.2024.124217_b0025","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000327568","article-title":"Future treatment option for hepatocellular carcinoma: a focus on brivanib","volume":"29","author":"Masatoshi","year":"2011","journal-title":"Digest. Dis."},{"key":"10.1016\/j.jchromb.2024.124217_b0030","doi-asserted-by":"crossref","unstructured":"A. Steven Robert, Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial, Am. J. Clin. Oncol. 35(2012)329-333, Doi: 10.1097\/COC.0b013e3182118cdf.","DOI":"10.1097\/COC.0b013e3182118cdf"},{"key":"10.1016\/j.jchromb.2024.124217_b0035","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.26898","article-title":"Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma","volume":"59","author":"Bryan","year":"2014","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.jchromb.2024.124217_b0040","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Robert","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jchromb.2024.124217_b0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000335963","article-title":"Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial","volume":"82","author":"Ahmed","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.jchromb.2024.124217_b0050","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1158\/1535-7163.MCT-09-0812","article-title":"ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways","volume":"9","author":"Alan","year":"2010","journal-title":"Mol. Cancer Therap."},{"key":"10.1016\/j.jchromb.2024.124217_b0055","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/cncr.27758","article-title":"Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma","volume":"119","author":"Toh","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jchromb.2024.124217_b0060","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.29496","article-title":"Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma","volume":"67","author":"Bouattour","year":"2018","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.jchromb.2024.124217_b0065","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-4614-6176-0_6","article-title":"Impact of genetic markers on treatment of non-small cell lung cancer\u201d","volume":"779","author":"Lamparella","year":"2013","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.jchromb.2024.124217_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114517","article-title":"Development and validation of an UPLC-MS\/MS method for simultaneous determination of fifteen targeted anti-cancer drugs in human plasma and its application in therapeutic drug monitoring","volume":"212","author":"Li","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2024.124217_b0075","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/bs.podrm.2019.10.004","article-title":"Erlotinib","volume":"45","author":"Abdelgalil","year":"2020","journal-title":"Profiles Drug Subst. Excip. Relat. Methodol."},{"key":"10.1016\/j.jchromb.2024.124217_b0080","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","article-title":"First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study","volume":"26","author":"Wu","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jchromb.2024.124217_b0085","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(18)30277-7","article-title":"Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial","volume":"6","author":"Yue","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.jchromb.2024.124217_b0090","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.lungcan.2010.11.007","article-title":"Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors","volume":"73","author":"Zhao","year":"2011","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.jchromb.2024.124217_b0095","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00280-014-2398-8","article-title":"Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects","volume":"73","author":"Liu","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jchromb.2024.124217_b0100","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","article-title":"First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study","volume":"28","author":"Shi","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jchromb.2024.124217_b0105","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(13)70355-3","article-title":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","volume":"14","author":"Shi","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jchromb.2024.124217_b0110","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cca.2011.09.012","article-title":"Development and clinical application of a LC-MS\/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma","volume":"413","author":"G\u00f6tze","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jchromb.2024.124217_b0115","article-title":"Development and validation of an UPLC-MS\/MS method for simultaneous determination of fifteen targeted anti-cancer drugs in human plasma and its application in therapeutic drug monitoring","volume":"212","author":"Li","year":"2022","journal-title":"J. Pharm. Biomed. Analy"},{"key":"10.1016\/j.jchromb.2024.124217_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.121968","article-title":"A simple and rapid liquid chromatography-mass spectrometry method to assay cabozantinib in plasma: application to therapeutic drug monitoring in patients with renal cell carcinoma","volume":"1138","author":"Ferrer","year":"2020","journal-title":"J. Chromatog. B"},{"key":"10.1016\/j.jchromb.2024.124217_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2019.121851","article-title":"Simultaneous quantitative determination of seven novel tyrosine kinase inhibitors in plasma by a validated UPLC-MS\/MS method and its application to human microsomal metabolic stability study","volume":"1136","author":"Ezzeldin","year":"2020","journal-title":"J. Chromatog. B"},{"key":"10.1016\/j.jchromb.2024.124217_b0130","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/FTD.0000000000000872","article-title":"A broad range high-throughput assay for lenvatinib using ultra-high performance liquid chromatography coupled to tandem mass spectrometry with clinical application in patients with hepatocellular carcinoma","volume":"43","author":"Sueshige","year":"2021","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jchromb.2024.124217_b0135","unstructured":"Food and Drug Administration(FDA), Bioanalytical Method Validation Guidance for Industry. 2018. Bioanalytical Method Validation Guidance for Industry (fda.gov), 2018."},{"key":"10.1016\/j.jchromb.2024.124217_b0140","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jpba.2018.12.036","article-title":"UPLC-MS\/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma","volume":"166","author":"Xu","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2024.124217_b0145","article-title":"In vivo pharmacokinetic drug-drug interaction studies between fedratinib and antifungal agents based on a newly developed and validated UPLC\/MS-MS method","volume":"11","author":"Tang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jchromb.2024.124217_b0150","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/13880209.2022.2048862","article-title":"Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC-MS\/MS assay","volume":"60","author":"Zhang","year":"2022","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.jchromb.2024.124217_b0155","article-title":"Determination of five mTOR inhibitors in human plasma for hepatocellular carcinoma treatment using QuEChERS-UHPLC-MS\/MS","volume":"235","author":"Wang","year":"2023","journal-title":"J. Pharm. Biomed. Analy."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224002265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023224002265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T18:40:55Z","timestamp":1720032055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023224002265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":31,"alternative-id":["S1570023224002265"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124217","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantification and analyses of seven tyrosine kinase inhibitors targeting hepatocellular carcinoma in human plasma by QuEChERS and UPLC-MS\/MS","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2024.124217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124217"}}